HRMY vs JAZZ
HRMY: Harmony Biosciences is a pharmaceutical company focused on delivering innovative therapies for rare neurological disorders, anchored by its commercial success in narcolepsy treatment. JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions.
Side-by-side fundamentals
| Metric | HRMY | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $39.60 | $222.45 | |
| Market cap | $2.3B | $14.4B | |
| P/E as of 2026-10-08 | 12.81 | 15.21 | HRMY lower |
| Net margin FY2025, SEC XBRL | +18.3% | -8.3% | HRMY higher |
| Gross margin FY2025, SEC XBRL | +77.2% | n/a | |
| Operating margin FY2025, SEC XBRL | +24.0% | -10.1% | HRMY higher |
| ROE FY2025, SEC XBRL | +18.2% | -8.2% | HRMY higher |
| ROA FY2025, SEC XBRL | +12.5% | -3.1% | HRMY higher |
| Debt / equity as of 2026-09-03 | 0.15 | 0.91 | HRMY lower |
| Revenue growth (YoY) as of 2026-09-03 | +24.3% | +12.6% | HRMY higher |
| Revenue CAGR (3y) SEC XBRL | +25.6% | +5.3% | HRMY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.61 | 0.75 | |
| 1-year return as of 2026-10-08 close | +49.1% | +61.5% | JAZZ higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.